Quantum BioPharma Shareholders Approve Corporate Direction at Annual Meeting

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced the results of its annual general and special meeting of shareholders held September 26, 2025, in Toronto. The meeting demonstrated significant shareholder engagement, with holders representing 12 Class A multiple voting shares and 1,769,228 Class B subordinate voting shares present in person or by proxy. This participation accounted for 100% of Class A votes and 46.352% of Class B votes, reflecting strong investor interest in the company's strategic direction and future prospects.

The shareholder meeting outcomes are particularly significant given Quantum BioPharma's focus on developing innovative treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's research and development pipeline includes drug candidates at various stages of development, with its lead compound Lucid-MS showing promise in preclinical models for preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. Additional details about the company's corporate developments are available at https://ibn.fm/D5GzF.

Quantum BioPharma's corporate structure includes its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is dedicated to advancing the Lucid-MS program. The patented new chemical entity represents a potential breakthrough in multiple sclerosis treatment, addressing the fundamental pathology of the disease rather than merely managing symptoms. This approach could have substantial implications for the approximately 2.8 million people worldwide living with multiple sclerosis, offering hope for disease modification rather than symptomatic relief alone.

The company's strategic investments extend beyond its core research programs through its subsidiary FSD Strategic Investments Inc., which manages loans secured by residential or commercial property. This diversified approach to asset management provides additional financial stability while the company advances its pharmaceutical research. Investors seeking comprehensive information about Quantum BioPharma's ongoing developments can access the company's newsroom at https://ibn.fm/QNTM.

Quantum BioPharma's intellectual property portfolio includes the unbuzzd(TM) technology, which has been spun out to Unbuzzd Wellness Inc. under an agreement that provides Quantum BioPharma with 20.11% ownership and royalty payments of 7% of sales until reaching $250 million, after which the royalty decreases to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical applications, preserving valuable future revenue streams and development opportunities in the growing wellness and pharmaceutical markets.

The successful shareholder meeting reflects confidence in Quantum BioPharma's management team and strategic vision at a time when the biopharmaceutical industry faces increasing regulatory scrutiny and development challenges. The strong voter turnout, particularly the complete representation of Class A multiple voting shares, indicates alignment between majority shareholders and company leadership regarding the direction of research programs and corporate strategy. This unity is crucial for navigating the complex regulatory landscape and advancing promising treatments through clinical development stages.